Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Daiichi Sankyo Co Ltd

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU® will be featured as late-breaker presentation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempedoic Acid,Ezetimibe

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nustendi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 16, 2020

            Details:

            Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prasugrel Hydrochloride

            Therapeutic Area: Neurology Product Name: Effient

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 15, 2020

            Details:

            This application for prasugrel HCl is based on the results of a phase 3 study in thrombotic stroke patients in Japan (PRASTRO-III study), as well as other phase 3 studies in Japan targeting patients with ischemic cerebrovascular disease (PRASTRO-I and PRASTRO-II studies).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Datopotamab Deruxtecan

            Therapeutic Area: Oncology Product Name: DS-1062a

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            TROPION-Lung01 was started after the encouraging clinical activity of datopotamab deruxtecan in patients with heavily pre-treated advanced NSCLC observed in the ongoing TROPION-PanTumor01 phase 1 trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Datopotamab Deruxtecan

            Therapeutic Area: Oncology Product Name: DS-1062a

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            The phase 1 trial of datopotamab deruxtecan will evaluate whether targeting TROP2 with DXd ADC technology could be a new treatment strategy for patients with previously treated metastatic non-small cell lung cancer with actionable genomic alterations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: DS-8201

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 11, 2020

            Details:

            Recommendation based on positive results from the DESTINY-Breast01 trial evaluating Trastuzumab, which showed durable responses in patients with previously treated disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Phase II Product Type: Large molecule

            Recipient: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 10, 2020

            Details:

            The updated data demonstrated that patients treated with Enhertu achieved an objective response rate (ORR) of 61.4% and a median duration of response (DoR) of 20.8 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan,Nivolumab

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 10, 2020

            Details:

            First data to show that ENHERTU may be safely combined with an immunotherapy agent, at therapeutic doses of both agents and for a meaningful treatment duration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Patritumab Deruxtecan

            Therapeutic Area: Oncology Product Name: U3-1402

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            Additional data to be presented at SABCS includes the initial safety and efficacy res